Medical Care Criteria Committee, updated August 2018
|A NEW HIV DIAGNOSIS IS A CALL TO ACTION|
Editor’s Note: In the medical literature, as in this guideline, the terms “acute HIV infection” and “primary HIV infection” both describe the period immediately after infection when the patient is viremic and has detectable p24 antigen and/or HIV RNA without diagnostic HIV antibodies. For consistency, the term “acute HIV infection” is used in these guidelines.
The term “recent infection” is generally used to describe the 6-month period after infection occurs. “Early infection” refers to both acute and recent infection, after which infection is defined as chronic.
Accumulating evidence supports a decision to begin HIV treatment at the time of diagnosis [Lundgren et al. 2015]. Initiation of antiretroviral therapy (ART) during acute infection may have a number of beneficial clinical outcomes, including improved preservation of immunologic function, significantly reduced time to viral suppression, and reduction of the viral reservoir, which could be important for cure strategies [Pires et al. 2004; Streeck et al. 2006; Koegl et al. 2009; Hocqueloux et al. 2010; Ananworanich et al. 2012; Buzon et al. 2012; Lafeuillade et al. 2012; Margolick et al. 2012; Phanuphak et al. 2012; Le et al. 2013; Saez-Cirion et al. 2013; Pilcher C et al. 2015]. The risk of sexual transmission of HIV during acute or recent infection is significantly higher than during chronic infection [Pilcher CD et al. 2004; Hollingsworth et al. 2008; Pinkerton 2008; Hollingsworth et al. 2015], this difference likely correlates with high levels of viremia and is consistent with other routes of transmission [Bellan et al. 2015]. The public health benefit of early initiation of ART is well documented, with a significant reduction of HIV transmission among virally suppressed individuals. Further, in September 2017, the NYSDOH endorsed the consensus from the Prevention Access Campaign that Undetectable = Untransmissable (“U = U”), which indicates that individuals with a durable (≥6 months) undetectable viral load will not sexually transmit HIV [NYSDOH 2017; PAC 2018].
Recognizing and diagnosing acute infection is crucial to linking patients to care early and presents an important opportunity for prevention. Factors that may contribute to the increased risk for transmission during acute infection include:
- Hyperinfectivity associated with both markedly high viral load levels (often much greater than 10 million viral copies/mm3) and increased infectiousness of the virus [Quinn et al. 2000; Ma et al. 2009].
- Missed HIV diagnosis [Chin et al. 2013] because the nonspecific flu- or mono-like symptoms during acute illness are frequently unrecognized; a diagnosis would prompt providers to recommend treatment and risk-reduction counseling that could reduce both viral load levels and high-risk behavior [Colfax et al. 2002; Steward et al. 2009; Fonner et al. 2012].
For many reasons, detection of acute HIV infection can be a very important link in the chain of prevention. Evidence demonstrates that patients with a recent diagnosis of HIV are more likely to reduce risk behaviors if they are given counseling at the time of testing [Steward et al. 2009; Fonner et al. 2012] and are linked to primary HIV care [Metsch et al. 2008]. In addition, for those who elect to initiate ART, their risk of transmission is significantly diminished [Cohen et al. 2011; Cohen et al. 2016].
Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012;7:e33948. [PubMed]
Bellan SE, Dushoff J, Galvani AP, et al. Reassessment of HIV-1 acute phase infectivity: Accounting for heterogeneity and study design with simulated cohorts. PLoS Med2015;12:e1001801. [PubMed]
Buzon M, Siess K, Sone A, et al. Treatment of early HIV infection reduces viral reservoir to levels found in elite controllers. 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012, Seattle. Abstract 151.
Chin T, Hicks C, Samsa G, et al. Diagnosing HIV infection in primary care settings: Missed opportunities. AIDS Patient Care STDS 2013;27:392-397. [PubMed]
Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016;375(9):830-839. [PubMed]
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505. [PubMed]
Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS 2002;16(11):1529-35. [PubMed]
Fonner VA, Denison J, Kennedy CE, et al. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev 2012;9:CD001224. [PubMed]
Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24(10):1598-601. [PubMed]
Hollingsworth TD, Anderson R, Fraser C. HIV-1 Transmission, by stage of infection. JID 2008;198:687-93. [PubMed]
Hollingsworth TD, Pilcher CD, Hecht FM, et al. High transmissibility during early HIV infection among men who have sex with men-San Francisco, California. J Infect Dis 2015;211:1757-1760. [PubMed]
Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009;14:277-283. [PubMed]
Lafeuillade A, Hittinger G, Lambry V, et al. Long-term control of HIV reservoir after a 2-year ART course at acute infection. Abstract 358. CROI; 2012 Mar 5-8; Seattle, WA.
Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218-230. [PubMed]
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015;373(9):795-807. [PubMed]
Ma ZM, Stone M, Piatak M Jr., et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009;83:3288-3297. [PubMed]
Margolick J, Apuzzo L, Tossonian H, et al. Effect of randomized HAART on viral suppression off therapy in patients with acute/early HIV infection. Abstract 356. CROI; 2012 Mar 5-8; Seattle, WA.
Metsch LR, Pereyra M, Messinger S, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008;47:577-584. [PubMed]
NYSDOH. Dear colleage letter. 2017 Sep. https://www.health.ny.gov/diseases/aids/ending_the_epidemic/docs/september_physician_letter.pdf [accessed 2018 Aug 21]
PAC. Prevention Access Campaign Consensus Statement: Risk of Sexual Transmission of HIV From a Person Living with HIV Who Has an Undetectable Viral Load. 2018 Jan 28. https://www.preventionaccess.org/consensus [accessed 2018 Aug 21]
Phanuphak N, Teeratakulpisarn N, Mungyu P, et al. Time to undetectable HIV RNA in ano-genital compartment of acute HIV Thai male subjects treated with 5- and 3-drug HAART. Abstract 555. CROI; 2012 Mar 5-8; Seattle, WA.
Pilcher C, Hatano H, Dasgupta A, et al. Providing same day, observed ART to newly diagnosed HIV+ outpatients is associated with improved virologic suppression. Abstract WEAD0105LB. International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2015); 2015 Jul 19-22; Vancouver, Canada.
Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: Acute HIV infection and the sexual transmission of J Infect Dis 2004;189:1785-1792. [PubMed]
Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 2007;21:1625-1629. [PubMed]
Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav2008;12:667-684. [PubMed]
Pires A, Hardy G, Gazzard B, et al. Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr 2004;36:783-790. [PubMed]
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929. [PubMed]
Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HcIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211. [PubMed]
Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 2009;13:1054-1060. [PubMed]
Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006;194:734-739. [PubMed]
Presentation and Diagnosis
Medical Care Criteria Committee, updated August 2018
NYS HIV Testing Requirements
When Acute HIV Infection Is Suspected
NYS Reporting Requirement and Partner Notification
Prevention Following a Negative HIV Test
The time from HIV infection to detection of the virus depends on the test that is used. Figure 1 illustrates the window of detection of HIV infection according to antibody, antibody/antigen combination, and HIV RNA tests.
Presentation: Patients acutely infected with HIV will often experience at least some symptoms of acute retroviral syndrome. Fever and flu- or mono-like symptoms are common in acute HIV infection but are nonspecific. Rash, mucocutaneous ulcers, oropharyngeal candidiasis, and meningismus are more specific and should raise the index of suspicion. See Acute Retroviral Syndrome for a more extensive list of signs and symptoms. The mean time from exposure to onset of symptoms is generally 2 to 4 weeks, with a range of 5 to 29 days; however, some cases have presented with symptoms up to 3 months after exposure [Apoola et al. 2002]. Theoretically, this time course may be prolonged in patients who become infected while on PEP or PrEP.
Diagnosis: Acute HIV infection is often not recognized in the primary care setting because the symptom profile is similar to that of influenza, mononucleosis, and other common illnesses. Furthermore, patients often do not recognize that they may have recently been exposed to HIV. Therefore, the clinician should have a high index of suspicion for acute HIV infection in a patient who may have recently engaged in behavior involving sexual or parenteral exposure to another person’s blood or body fluids and who is presenting with a febrile, flu-, or mono-like illness. Identification of acute HIV infection during pregnancy is particularly important to ensure appropriate steps are taken to prevent mother-to-child transmission [Patterson et al. 2007].
When clinicians suspect acute infection, a test for plasma HIV RNA should be performed. High levels of HIV RNA detected in plasma through use of sensitive nucleic acid amplification testing (NAAT), in combination with a negative or indeterminate HIV screening or type-differentiation test, support the presumptive diagnosis of acute HIV infection.
When low-level viremia is reported by HIV RNA testing (<5000 copies/mL) in the absence of serologic evidence of HIV infection, HIV RNA testing should be repeated to exclude a false-positive result [Hecht et al. 2002]. Repeat HIV RNA testing with a result of low-level viremia may represent true HIV infection, warranting appropriate counseling regarding transmission risk. ART should be recommended in the setting of low-level viremia that has been confirmed by repeat HIV RNA testing.
HIV RNA levels tend to be very high in acute infection; however, a low value may represent any point on the upward or downward slope of the viremia associated with acute infection or could simply represent chronic infection. Plasma HIV RNA levels during acute infection do not appear significantly different in patients who have symptoms versus those who are asymptomatic [Pilcher et al. 2004]. Viremia occurs approximately 2 weeks prior to the detection of a specific immune response. Patients diagnosed with acute infection by HIV RNA testing should always receive follow-up diagnostic testing 3 weeks later to confirm infection (see the CDC HIV testing algorithm) [CDC 2013, 2014]. Figure 2 illustrates diagnostic testing for acute HIV infection.
|KEY POINTS IN ACUTE HIV DIAGNOSTIC TESTING|
Apoola A, Ahmad S, Radcliffe K. Primary HIV infection. Int J STD AIDS 2002;13:71-78. [PubMed]
CDC. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm – United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013;62(24):489-494. [PubMed]
CDC. Laboratory testing for the diagnosis of HIV infection: updated recommendations. 2014 Jun 27. https://stacks.cdc.gov/view/cdc/23447 [accessed 2018 Aug 24]
Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002;16:1119-1129. [PubMed]
Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 2006;42(1):75-9. [PubMed]
Patterson KB, Leone PA, Fiscus SA. Frequent detection of acute HIV infection in pregnant women. AIDS 2007;21(17):2303-8. [PubMed]
Pilcher CD, Price MA, Hoffman IF, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004;18:517-524. [PubMed]
Acute Retroviral Syndrome
Associated signs and symptoms (expected frequency among patients who are symptomatic):
- Fever (80%)
- Tired or fatigued (78%)
- Malaise (68%)
- Arthralgias (joint pain) (54%)
- Headache (54%)
- Loss of appetite (54%)
- Rash (51%)
- Night sweats (51%)
- Myalgias (pain in muscles) (49%)
- Nausea (49%)
- Diarrhea (46%)
- Fever and rash (46%)
- Pharyngitis (sore throat) (44%)
- Oral ulcers (mouth sores) (37%)
- Stiff neck (34%)
- Weight loss (>5 lb; 2.5 kg) (32%)
- Confusion (25%)
- Photophobia (24%)
- Vomiting (12%)
- Infected gums (10%)
- Sores on anus (5%)
- Sores on genitals (2%)
Data are from Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002;16:1119-1129.
*The most specific symptoms in this study were oral ulcers and weight loss. Best predictors were fever and rash. Index of suspicion should be high when these symptoms are present.
Management, Including While on PEP or PrEP
Medical Care Criteria Committee, August 2020
Managing Acute HIV
Patients are at greatest risk for transmitting HIV during periods of high viremia early in infection. Clinicians should counsel patients with acute HIV about the increased risk of transmission during the 6 months after infection. Partner notification [Golden, et al. 2004], counseling on safer sex, and screening for other sexually transmitted infections are all important in the management of any new HIV diagnosis.
Consult an Experienced HIV Care Provider
- When choosing an ART regimen for a patient with acute HIV infection, a care provider experienced in the treatment of acute HIV infection should be consulted.
- Data are insufficient to support firm recommendations regarding specific regimens for treating acute HIV infection.
- The risks of transmitted resistance should be considered when prescribing ART while awaiting HIV resistance results.
Clinicians who do not have access to experienced HIV care providers should call the CEI Line at 1-866-637-2342.
Rationale for early treatment: The NYSDOH AI HIV Clinical Guidelines Program and the U.S. Department of Health and Human Services recommend initiation of ART for all patients with a confirmed HIV diagnosis regardless of their CD4 cell count or viral load. Initiation of ART is associated with the following benefits for the individual with HIV:
- Reduced morbidity and mortality [Zolopa, et al. 2009; Lundgren, et al. 2015].
- Reduced risk of transmission to others [Cohen, et al. 2016].
- Improved immunologic recovery (CD4 T cell counts) [Jain, et al. 2013].
- Reduced HIV reservoir [Jain, et al. 2013].
- Reduced treatment delays and improved retention in care and viral suppression at 12 months [Ford, et al. 2018].
- See the NYSDOH guideline When to Initiate ART, With Protocol for Rapid Initiation > Rationale for Rapid ART Initiation for more information.
The rationale for early treatment (CD4 count >500 cells/mm3) in chronic HIV infection was definitively demonstrated in preliminary results from the START study, in which there was a 53% reduction in serious illness or death among individuals who received early treatment [Lundgren, et al. 2015].
In 3 randomized controlled studies that compared deferred versus immediate initiation of ART for acute or recent HIV infection [Grijsen, et al. 2012; Hogan, et al. 2012; Fidler, et al. 2013], immediate initiation of ART delayed a decrease in CD4 counts to <350 cells/mm3 compared with no therapy. A notable finding across these studies is the high percentage of patients who deferred therapy who progressed to CD4 counts <350 cells/mm3 within the first year after infection, suggesting that if initiation of ART is postponed, most patients will experience significant immune decline fairly rapidly.
Although these studies may have oversampled symptomatic patients, a population in whom disease progresses more rapidly [Vanhems, et al. 1998; Lavreys, et al. 2006], previous estimates that included more asymptomatic patients indicated an average time of 1.5 years after seroconversion for CD4 counts to decline to <350 cells/mm3 [CASCADE 2000]. These findings suggest that the amount of time off therapy gained by deferring initiation is limited, relative to the need for lifelong treatment.
Notably, these studies used an outdated recommended CD4 count threshold of <350 cells/mm3 instead of current recommendations for early treatment at any CD4 count, including CD4 counts >500 cells/mm3, and investigated various durations of ART followed by treatment interruption [Grijsen, et al. 2012; Hogan, et al. 2012; Fidler, et al. 2013]. Because there is evidence that treatment interruptions carry significant risks of morbidity and mortality [El-Sadr, et al. 2006], as well as increased transmission risk during viral rebound [Rieder, et al. 2010; Hamlyn, et al. 2012], the findings regarding treatment interruption no longer have relevance for individualized treatment decisions in the context of acute or chronic HIV infection.
The risks and benefits of early ART to discuss with patients when making the decision of whether and when to initiate ART are outlined below. It should be emphasized that the START trial provided definitive evidence that the benefits of early initiation of ART outweigh the potential disadvantages.
Benefits of early ART in asymptomatic patients (early therapy = initiation at CD4 counts >500 cells/mm3):
- Reduction in HIV-related and non–HIV-related morbidity and mortality [Phillips, et al. 2007; Kitahata, et al. 2009; Marin, et al. 2009; Sterne, et al. 2009; Ray, et al. 2010; Silverberg, et al. 2011; Ho, et al. 2012; Lewden, et al. 2012; Lundgren, et al. 2015].
- Delay or prevention of immune system compromise [Lewden, et al. 2007].
- Possible lower risk of antiretroviral resistance [Uy, et al. 2009].
- Decreased risk of sexual transmission of HIV [Quinn, et al. 2000; Castilla, et al. 2005; Donnell, et al. 2010; Cohen, et al. 2011]. HIV cannot be transmitted sexually when the plasma viral load is undetectable; ART is not a substitute for primary HIV prevention measures, such as avoidance of needle sharing [Politch, et al. 2012].
- Decreased risk of several severe bacterial infections [O’Connor, et al. 2017].
- Potential decrease in size of viral reservoir and preservation of gut-associated lymphoid tissue with initiation during acute HIV, i.e., within the first 6 weeks [Jain, et al. 2013; Novelli, et al. 2018].
Disadvantages of early ART in asymptomatic patients:
- Possibility of greater cumulative side effects from ART [Volberding and Deeks 2010].
- Possibility for earlier development of drug resistance and limitation in future [Barth, et al. 2012] antiretroviral options if adherence and viral suppression are suboptimal.
- Possibility for earlier onset of treatment fatigue.
Genotypic resistance testing: The increasing incidence of transmission of antiretroviral resistance [Kim, et al. 2013] argues for resistance testing at baseline in all individuals with HIV, including those who are acutely infected. Antiretroviral drug resistance mutations are more likely to be detected when genotypic resistance testing is performed at the time of recent infection [Kim, et al. 2013]. Genotypic resistance testing that includes the protease, reverse transcriptase, and integrase genes should be obtained at diagnosis (or initial visit if not done previously), but ART initiation should not be delayed pending the results [Borroto-Esoda, et al. 2007; Kuritzkes, et al. 2008].
To identify the potential for preexisting drug-resistant virus, the initial assessment should also include the patient’s history of PrEP and PEP use and previous ART use for people who are re-engaging in care [Ford, et al. 2018]. See the NYSDOH AI guideline When to Initiate ART, With Protocol for Rapid Initiation > Medical and Psychosocial Assessment for details on taking a medical history before ART initiation.
Clinicians should perform baseline laboratory testing listed in Box 1: Baseline Laboratory Testing Checklist, below, for all patients who are initiating ART immediately; ART can be started while awaiting laboratory test results. If ART is initiated during acute HIV infection, it should be continued indefinitely because viremia has been documented to reappear or increase after discontinuation of therapy, and treatment interruptions lead to greater morbidity and mortality [El-Sadr, et al. 2006].
|Box 1: Baseline Laboratory Testing Checklist|
Whether or not ART for acute HIV infection is initiated, follow-up with standard HIV testing and HIV primary care should be arranged (see the NYSDOH AI guidelines HIV Testing and Primary Care Approach).
Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012;17(2):377-386. [PMID: 22297391]
Borroto-Esoda K, Waters JM, Bae AS, et al. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses 2007;23(8):988-995. [PMID: 17725415]
CASCADE. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000;1(4):224-231. [PMID: 11737353]
Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40(1):96-101. [PMID: 16123689]
Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375(9):830-839. [PMID: 27424812]
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505. [PMID: 21767103]
Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010;375(9731):2092-2098. [PMID: 20537376]
El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283-2296. [PMID: 17135583]
Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-217. [PMID: 23323897]
Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS 2018;32(1):17-23. [PMID: 29112073]
Golden MR, Hogben M, Potterat JJ, et al. HIV partner notification in the United States: a national survey of program coverage and outcomes. Sex Transm Dis 2004;31(12):709-712. [PMID: 15608584]
Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012;9(3):e1001196. [PMID: 22479156]
Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012;7(8):e43754. [PMID: 22952756]
Ho JE, Scherzer R, Hecht FM, et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012;26(9):1115-1120. [PMID: 22382147]
Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012;205(1):87-96. [PMID: 22180621]
Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208(8):1202-1211. [PMID: 23852127]
Kim D, Ziebell R, Saduvala N. Trend in transmitted HIV-1 antiretroviral drug resistance-associated mutations, 10 HIV surveillance areas, United States, 2007-2010. Abstract 149. CROI; 2013 Mar 3-6; Atlanta, GA. https://www.cdc.gov/nchhstp/newsroom/2013/croi-studies-of-interest.html
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815-1826. [PMID: 19339714]
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008;197(6):867-870. [PMID: 18269317]
Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006;42(9):1333-1339. [PMID: 16586394]
Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41(2):433-445. [PMID: 22493325]
Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46(1):72-77. [PMID: 17621240]
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795-807. [PMID: 26192873]
Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009;23(13):1743-1753. [PMID: 19571723]
Novelli S, Lecuroux C, Avettand-Fenoel V, et al. Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis 2018;66(10):1519-1527. [PMID: 29211834]
O’Connor J, Vjecha MJ, Phillips AN, et al. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per muL: secondary outcome results from a randomised controlled trial. Lancet HIV 2017;4(3):e105-e112. [PMID: 28063815]
Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007;21(13):1717-1721. [PMID: 17690569]
Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS 2012;26(12):1535-1543. [PMID: 22441253]
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342(13):921-929. [PMID: 10738050]
Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24(1):123-137. [PMID: 19770621]
Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010;24(8):1177-1183. [PMID: 20386427]
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2551-2559. [PMID: 22109347]
Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373(9672):1352-1363. [PMID: 19361855]
Uy J, Armon C, Buchacz K, et al. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009;51(4):450-453. [PMID: 19474757]
Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998;26(2):323-329. [PMID: 9502449]
Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010;376(9734):49-62. [PMID: 20609987]
Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4(5):e5575. [PMID: 19440326]
Medical Care Criteria Committee, updated August 2018
|ALL RECOMMENDATIONS: DIAGNOSIS AND MANAGEMENT OF ACUTE HIV|
NYS HIV Testing Requirements
When Acute HIV Infection Is Suspected
NYS Reporting Requirement and Partner Notification
Prevention Following a Negative HIV Test
Managing Acute HIV
Updates to this Guideline
The following updates were made in the section Management, Including While on PEP or PrEP :
- Rating change from A2 to A1: Clinicians should recommend antiretroviral therapy (ART) to all patients diagnosed with acute HIV infection.
- New recommendations:
- As part of the initial management of patients diagnosed with acute HIV infection, clinicians should obtain HIV genotypic resistance testing for the protease (A2), reverse transcriptase (A2), and integrase (B2) genes at the time of diagnosis.
- Clinicians should perform baseline laboratory testing listed in Box 1: Baseline Laboratory Testing Checklist for all patients who are initiating ART immediately; ART can be started while awaiting laboratory test results. (A3)
- Discussion revised:
- Rationale for early treatment
- Benefits and disadvantages of early treatment
- Genotypic resistance testing
- Addition: Box 1: Baseline Laboratory Testing Checklist
- Added “A New HIV Diagnosis is a Call to Action”
- Added a statement regarding U =U
- Presentation and Diagnosis:
- Updated the recommendation regarding HIV testing to reflect current NYS law, which mandates that physicians offer an HIV test to all patients aged 13 years and older, i.e., the previous upper age limit of 65 years was removed.
- Changed the text that follows from a key point to a recommendation: Diagnostic HIV RNA testing should be considered for patients who present with compatible symptoms (see Acute Retroviral Syndrome), particularly in the context of a sexually transmitted infection [Patel et al. 2006] or a recent sexual or parenteral exposure with a partner known to have HIV or a partner whose HIV serostatus is not known (A2).
- Updated links to open the January 2018 update to the CDC’s HIV testing algorithm
- Added two recommendations from the NYSDOH AI guideline PrEP to Prevent HIV and Promote Sexual Health to address prevention following a negative HIV test result.
- Added a Key Point: A negative screening test in response to suspected acute HIV infection is an opportunity to offer or refer the individual for PrEP. See the NYSDOH AI guideline PrEP to Prevent HIV and Promote Sexual Health.